Canaan Partners IX LLC is Director & 10% Owner at CytomX Therapeutics, Inc. (CTMX). They have made 9 open-market trades across 1 company since 2016, most recently 2020-10-14.
CIK 0001654586
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 56% | 44% | 0% |
| Avg Move | +1.0% | -0.2% | +10.6% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTMX | SELL | 2016-11-29 | 2016-12-01 | $11.18 | $247K | +12.0% | +4.0% | +29.0% |
| CTMX | SELL | 2016-11-23 | 2016-11-28 | $11.55 | $444K | +8.1% | +0.4% | +9.2% |
| CTMX | SELL | 2016-11-17 | 2016-11-21 | $11.61 | $526K | -7.6% | -3.3% | +0.3% |
| CTMX | SELL | 2016-11-15 | 2016-11-16 | $11.51 | $593K | -1.5% | +6.0% | +2.8% |
| CTMX | SELL | 2016-11-09 | 2016-11-10 | $11.03 | $151K | +4.8% | +4.9% | +1.4% |
| CTMX | SELL | 2016-06-08 | 2016-06-10 | $10.07 | $487K | -6.4% | +4.5% | +26.5% |
| CTMX | SELL | 2016-05-27 | 2016-06-01 | $10.60 | $266K | -5.5% | -2.2% | +9.7% |
| CTMX | SELL | 2016-05-25 | 2016-05-27 | $10.34 | $531K | -3.7% | -10.8% | +4.9% |
| CTMX | SELL | 2016-05-19 | 2016-05-23 | $10.10 | $88K | +8.4% | -5.1% | +11.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.